近年来研究表明,白血病、淋巴瘤和多发性骨髓瘤常常有一条或多条细胞凋亡通路发生异常,决定了此类细胞的存活率高于相应的正常细胞。而且,细胞凋亡应答异常对白血病和淋巴瘤细胞耐药性的产生至关重要。对凋亡机制的深入研究,促进了对许多凋亡靶标分子的识别,从而推动了以癌细胞中表达异常或失调的抗凋亡分子为靶标的新药研发。本文介绍了涉及凋亡的药物靶标和相关药物,以及其对白血病和淋巴瘤细胞的作用。 In recent years, studies have shown that leukemia, lymphoma and multiple myeloma often have one or more apoptosis pathway abnormalities, determines the survival rate of such cells is higher than the corresponding normal cells. Moreover, aberrant apoptotic responses are crucial for the development of drug resistance in leukemia and lymphoma cells. In-depth study of the apoptotic mechanism has led to the identification of many apoptotic target molecules, thereby promoting the development of new drugs targeting anti-apoptotic molecules that express abnormalities or disorders in cancer cells. This article describes the drug targets involved in apoptosis and related drugs, and their effects on leukemia and lymphoma cells.